RENVELA

Drug SANOFI-AVENTIS U.S. LLC
Total Payments
$158,080
Transactions
2,288
Doctors
1,251
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2019 $25,664 8 1
2018 $266.62 14 14
2017 $132,149 2,266 1,246

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,829 10 50.5%
Food and Beverage $40,183 2,244 25.4%
Travel and Lodging $27,238 24 17.2%
Unspecified $5,498 7 3.5%
Consulting Fee $5,332 3 3.4%

Payments by Type

General
$152,582
2,281 transactions
Research
$5,498
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease GENZYME CORPORATION $5,498 7

Top Doctors Receiving Payments for RENVELA — Page 50

Doctor Specialty Location Total Records
, MD Nephrology Hammond, IN $11.21 1
, MD Nephrology Norfolk, VA $11.19 1
, MD Nephrology Chicago, IL $11.19 1
, M.D Nephrology Evergreen Park, IL $11.18 1
, MD Specialist Freeport, NY $11.13 1
, M.D Internal Medicine Maywood, IL $11.08 1
, MD Nephrology Columbus, OH $11.05 1
, MD Nephrology Norfolk, VA $11.01 1
, M.D Nephrology Flowood, MS $10.95 1
, M.D Nephrology Poland, OH $10.90 1
, M.D Nephrology Danville, VA $10.79 1
, M.D Internal Medicine Little Rock, AR $10.78 1
, MD Nephrology Portsmouth, VA $10.74 1
, MD Specialist Euclid, OH $10.65 1
, M.D Nephrology Waldorf, MD $10.61 1
, MD Nephrology Springfield, OH $10.61 1
, MD, PHD Internal Medicine Meridian, ID $10.59 1
, MD Internal Medicine Meridian, ID $10.59 1
, MD Nephrology Canton, OH $10.56 1
, MD Nephrology Tallahassee, FL $10.56 1
, M.D Nephrology Woodbridge, VA $10.55 1
, MD Nephrology Houston, TX $10.52 1
, M.D Nephrology El Paso, TX $10.45 1
, D.O Nephrology South Gate, CA $10.45 1
, M.D Nephrology Clairton, PA $10.39 1

About RENVELA

RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.

Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.

The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).

RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).